Cardiff Oncology (CRDF) said Tuesday that preliminary results from a mid-stage study of its cancer treatment candidate onvansertib showed an overall 57% objective response rate, or ORR, in patients with a specific metastatic colorectal cancer.
Patients who received a 30 milligram dose of onvansertib in addition to standard of care had a 64% ORR, while those who received 20 milligram plus standard of care had a 50% ORR, Cardiff said.
Cardiff reported a "deeper tumor response" in those who received a 30 milligram dose compared with those who received 20 milligram.
The safety profiles of both doses are similar, with no major or unexpected toxicities observed, the company added.
The company said it plans to report additional data from the ongoing study in the first half of next year.
Shares of the company were up nearly 40% in recent Tuesday premarket activity.
Price: 3.40, Change: +0.96, Percent Change: +39.34
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。